Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Moderate Buy” by Brokerages

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $21.38.

A number of research analysts have weighed in on YMAB shares. Oppenheimer started coverage on Y-mAbs Therapeutics in a report on Monday. They issued an “outperform” rating and a $23.00 price objective on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research note on Friday, November 15th. Wedbush restated an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, September 9th.

Insider Buying and Selling

In other news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The trade was a 14.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the transaction, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This represents a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 100,000 shares of company stock worth $1,338,100. Company insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several institutional investors have recently bought and sold shares of YMAB. Squarepoint Ops LLC boosted its stake in shares of Y-mAbs Therapeutics by 143.4% in the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after purchasing an additional 74,452 shares during the period. SG Americas Securities LLC acquired a new stake in Y-mAbs Therapeutics during the 3rd quarter worth approximately $178,000. Millennium Management LLC lifted its holdings in Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after buying an additional 67,233 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after buying an additional 65,732 shares during the period. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after acquiring an additional 1,056 shares in the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Stock Down 2.9 %

Shares of NASDAQ YMAB opened at $10.54 on Thursday. The firm has a market cap of $472.09 million, a price-to-earnings ratio of -19.52 and a beta of 0.68. The company’s 50-day simple moving average is $13.82 and its 200-day simple moving average is $12.95. Y-mAbs Therapeutics has a 52-week low of $5.17 and a 52-week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. During the same quarter in the previous year, the firm posted ($0.18) earnings per share. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.